Novartis Ag (NYSE: NVS)
Novartis Ag Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Novartis Ag Company Info
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
News & Analysis
Top Commercial Real Estate Stocks
Commercial real estate stocks offer opportunities to get involved with some of the most interesting businesses in the world.
How AI Is Used in Healthcare
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Investors were caught off guard by a decision on the research and development front.
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
2 Magnificent Dividend Stocks to Hold for the Next Decade
The dividend is just one reason to buy these stocks.
Why Novartis Stock Topped the Market on Tuesday
A double beat on the latest quarterly results and raised guidance made investors happy.
1 Magnificent Dividend Stock to Buy and Hold
The company's business went through some important changes last year.
2 Dividend Stocks to Buy and Hold Forever
These businesses look too strong to fail.
Valuation
Podcast Episodes
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
What Happened With CAR-T Stocks in 2018
Here’s how CAR-T therapies did in their first full year on the market.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Washington Cuts a Check to Spark Healthcare Innovation
The 21st Century Cures Act ignites innovation with perks to biopharma and medical device makers. Also, Kite Pharma and Novartis prep plans to pitch their CAR-T cancer therapies to the FDA.
Earnings Transcripts
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
NVS earnings call for the period ending June 30, 2024.
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
NVS earnings call for the period ending March 31, 2024.
Novartis Ag (NVS) Q4 2023 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2023.
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.